Clinical Trial Update: Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease [Phase 2]

View source ↗

Summary

This clinical trial update reports the safety, tolerability, and preliminary efficacy results from a Phase 2 study of Dynacirc CR in Parkinson disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Dynacirc CR (isradipine)

Snippet

Sponsor: Northwestern University | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED | Results posted: 2013-04-17